drugset / Trial / NCT01067807

Proellex Pharmacokinetics Bridging Study

NCT01067807

Phase 1 Completed 21 enrolled Repros Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations

Timeline

Start
2007-06
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg
Subject Telapristone Acetate Other / unclassified 50 mg

Indications

No indication recorded.